Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 08/29 11:47:54 am
349.86 USD   +0.85%
1d ago REGENERON PHARMACEUTICALS : Assigned Patent
4d ago NASDAQ 100 MOVERS : Intu, gild
08/20 REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations ..
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/25/2014 08/26/2014 08/27/2014 08/28/2014 08/29/2014 Date
347.91(c) 354.05(c) 350.01(c) 346.92(c) 349.86 Last
449 724 668 654 439 481 401 786 180 960 Volume
+2.09% +1.76% -1.14% -0.88% +0.85% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
09/02 | 08:30amSpecial Situation
Surperformance© rating of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More about the company
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 812 M
EBIT 2014 1 046 M
Net income 2014 423 M
Finance 2014 1 257 M
Yield 2014 -
Sales 2015 3 506 M
EBIT 2015 1 461 M
Net income 2015 771 M
Finance 2015 2 440 M
Yield 2015 -
PER 2014 93,08
PER 2015 53,11
EV / Sales 2014 12,0x
EV / Sales 2015 9,30x
Capitalization 35 062 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
1d ago REGENERON PHARMACEUTICALS : Assigned Patent
4d ago NASDAQ 100 MOVERS : Intu, gild
08/20 REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations for I..
08/20 REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Report on..
08/20 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives EU Approval fo..
08/19 REGENERON PHARMACEUTICALS : Announces Upcoming 2014 Investor Conference Presenta..
08/13 REGENERON PHARMACEUTICALS : Robbins Arroyo LLP Is Investigating the Officers and..
08/13 REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
08/12 REGENERON PHARMACEUTICALS : Financial Results, Study Results, and Proposed Merge..
08/12 REGENERON PHARMACEUTICALS : Bayer Receives EU Approval for EYLEA in Diabetic Mac..
08/11 REGENERON PHARMACEUTICALS : Assigned Patent
08/11 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives EU Approval ..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
EPS Revisions
Regeneron Pharmaceuticals  : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF